Published in Neurobiol Dis on May 27, 2014
Omega-3 Fatty Acids Augment the Actions of Nuclear Receptor Agonists in a Mouse Model of Alzheimer's Disease. J Neurosci (2015) 1.03
Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease. J Neurosci (2015) 0.99
Activation of PPARδ: from computer modelling to biological effects. Br J Pharmacol (2014) 0.97
APOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective. J Neurochem (2015) 0.96
Insulin resistance in Alzheimer's disease. Neurobiol Dis (2014) 0.88
PPARγ and the Innate Immune System Mediate the Resolution of Inflammation. PPAR Res (2015) 0.85
Targeting innate immunity for neurodegenerative disorders of the central nervous system. J Neurochem (2016) 0.85
RXR controlled regulatory networks identified in mouse brain counteract deleterious effects of Aβ oligomers. Sci Rep (2016) 0.81
LXR Regulation of Brain Cholesterol: From Development to Disease. Trends Endocrinol Metab (2016) 0.81
Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice. J Biol Chem (2015) 0.79
Telomere shortening leads to an acceleration of synucleinopathy and impaired microglia response in a genetic mouse model. Acta Neuropathol Commun (2016) 0.75
Neuronally-directed effects of RXR activation in a mouse model of Alzheimer's disease. Sci Rep (2017) 0.75
Liver X receptor agonist treatment significantly affects phenotype and transcriptome of APOE3 and APOE4 Abca1 haplo-deficient mice. PLoS One (2017) 0.75
Ligand dependent switch from RXR homo- to RXR-NURR1 heterodimerization. ACS Chem Neurosci (2017) 0.75
Nuclear receptors in neural stem/progenitor cell homeostasis. Cell Mol Life Sci (2017) 0.75
Alternative activation of macrophages: mechanism and functions. Immunity (2010) 12.43
Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature (2007) 11.59
ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science (2012) 10.42
Nuclear receptors and lipid physiology: opening the X-files. Science (2001) 8.76
Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology (1996) 7.92
Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A (1997) 7.07
Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest (2006) 4.92
ApoE promotes the proteolytic degradation of Abeta. Neuron (2008) 4.75
A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell (2009) 4.60
CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol (2011) 4.12
PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease. Cell (2011) 4.00
Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol (2010) 3.60
Alternative macrophage activation and metabolism. Annu Rev Pathol (2011) 3.59
Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol (2000) 3.37
Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol (2009) 3.04
Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity (2009) 2.99
Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science (2000) 2.90
Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience (2004) 2.84
Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. Genes Dev (2009) 2.47
Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu Rev Med (2006) 2.44
Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol (2006) 2.42
The NR4A subgroup: immediate early response genes with pleiotropic physiological roles. Nucl Recept Signal (2006) 2.35
Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain (2005) 2.27
Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci (2003) 2.27
PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance. Nat Med (2009) 2.21
Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol (2004) 2.21
PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J Neurosci (2012) 2.12
Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci U S A (2007) 2.06
Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci (2000) 2.03
Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes. Mol Cell (2009) 1.91
Liver X receptors and oxysterols promote ventral midbrain neurogenesis in vivo and in human embryonic stem cells. Cell Stem Cell (2009) 1.84
Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A (2006) 1.81
Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci (2003) 1.76
The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem (2004) 1.75
Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci (2008) 1.73
Nuclear receptors, mitochondria and lipid metabolism. Mitochondrion (2008) 1.71
Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J Neurosci (2012) 1.71
Cellular expression of the immediate early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system. Brain Res Mol Brain Res (1996) 1.70
Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr Opin Genet Dev (2008) 1.66
The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci (2007) 1.66
Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc Natl Acad Sci U S A (2002) 1.65
Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis (2006) 1.65
Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science (2013) 1.64
ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. J Biol Chem (2010) 1.64
Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem (2004) 1.61
Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem (2002) 1.61
Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease. Exp Neurol (2012) 1.60
Essential role for DNA-PK-mediated phosphorylation of NR4A nuclear orphan receptors in DNA double-strand break repair. Genes Dev (2011) 1.60
Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science (2013) 1.54
In vivo activation of PPAR target genes by RXR homodimers. EMBO J (2004) 1.53
Microglial dysfunction in brain aging and Alzheimer's disease. Biochem Pharmacol (2014) 1.52
Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science (2013) 1.50
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur J Neurosci (2009) 1.48
Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice. J Neurosci (2010) 1.48
The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci (2005) 1.47
Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol (2005) 1.46
Nuclear receptors as therapeutic targets for Alzheimer's disease. Expert Opin Ther Targets (2011) 1.46
Differential expression of cholesterol hydroxylases in Alzheimer's disease. J Biol Chem (2004) 1.46
Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurol (2013) 1.45
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord (2010) 1.45
The immune system as a sensor of the metabolic state. Immunity (2013) 1.45
Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science (2013) 1.45
Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Hum Mol Genet (2011) 1.44
Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Cell Mol Life Sci (2011) 1.42
Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer's β-amyloidosis mouse model. J Neurosci (2011) 1.41
Microglia development and function. Annu Rev Immunol (2014) 1.41
The immunology of neurodegeneration. J Clin Invest (2012) 1.41
α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med (2012) 1.40
The orphan nuclear receptor Nurr1 restricts the proliferation of haematopoietic stem cells. Nat Cell Biol (2010) 1.40
Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice. Proc Natl Acad Sci U S A (2005) 1.40
Peroxisome proliferator-activated receptor delta regulation of miR-15a in ischemia-induced cerebral vascular endothelial injury. J Neurosci (2010) 1.38
PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics (2008) 1.36
Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol Psychiatry (2009) 1.34
The retinoid X receptors and their ligands. Biochim Biophys Acta (2011) 1.32
Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system. Mol Endocrinol (2002) 1.31
Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis. J Neuroimmunol (2005) 1.29
The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs (2008) 1.26
Liver X receptor beta (LXRbeta): a link between beta-sitosterol and amyotrophic lateral sclerosis-Parkinson's dementia. Proc Natl Acad Sci U S A (2008) 1.26
miR-132 regulates the differentiation of dopamine neurons by directly targeting Nurr1 expression. J Cell Sci (2012) 1.21
Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science (2013) 1.21
Molecular pathways: the role of NR4A orphan nuclear receptors in cancer. Clin Cancer Res (2012) 1.21
Critical role of astroglial apolipoprotein E and liver X receptor-α expression for microglial Aβ phagocytosis. J Neurosci (2011) 1.20
Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo. J Pharmacol Exp Ther (2006) 1.19
The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation (2011) 1.19
Insulin and Alzheimer's disease: untangling the web. J Alzheimers Dis (2013) 1.19
Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-beta. Proc Natl Acad Sci U S A (2011) 1.19
In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol Neurodegener (2013) 1.17
Increased infarct size and lack of hyperphagic response after focal cerebral ischemia in peroxisome proliferator-activated receptor beta-deficient mice. J Cereb Blood Flow Metab (2006) 1.16
Research resource: transcriptome profiling of genes regulated by RXR and its permissive and nonpermissive partners in differentiating monocyte-derived dendritic cells. Mol Endocrinol (2010) 1.15
Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem Biophys Res Commun (2008) 1.15
Omega-3 fatty acids in anti-inflammation (pro-resolution) and GPCRs. Prog Lipid Res (2012) 1.13
Regulation of microglia activation and deactivation by nuclear receptors. Glia (2012) 1.13
Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene. J Neurosci (2014) 1.13
Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. Mol Neurodegener (2013) 1.13
Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment. Mol Neurodegener (2007) 1.13
Retinoid X receptor alpha controls innate inflammatory responses through the up-regulation of chemokine expression. Proc Natl Acad Sci U S A (2010) 1.13
Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology (2010) 1.12
Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp Neurol (2005) 1.10
Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease. ACS Chem Neurosci (2013) 1.10